These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30683837)

  • 41. [A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Li B; Yan X; Shi ZX; Huang HJ; Liu D; Cai YN; Zhang YD; Zhang PH; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):12-16. PubMed ID: 30704222
    [No Abstract]   [Full Text] [Related]  

  • 42. [An autopsy case of primary myelofibrosis terminating in leukemic transformation (author's transl)].
    Kamiyama R; Ishii Z; Takemura T; Enomoto H; Hanaoka M
    Rinsho Ketsueki; 1977 Oct; 18(10):1253-9. PubMed ID: 592501
    [No Abstract]   [Full Text] [Related]  

  • 43. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells.
    Kimura A; Kawaishi K; Nakata Y; Hyodo H; Kuramoto A; Satow Y
    Leuk Lymphoma; 1995 Nov; 19(5-6):493-8. PubMed ID: 8590852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
    Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
    Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Leukemic risk in thrombocythemia].
    Liozon E; Turlure P
    Ann Med Interne (Paris); 1998 Mar; 149(2):82-6. PubMed ID: 11490529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis.
    Lucijanic M; Livun A; Stoos-Veic T; Pejsa V; Jaksic O; Cicic D; Lucijanic J; Romic Z; Orehovec B; Aralica G; Miletic M; Kusec R
    Hematology; 2018 May; 23(4):201-207. PubMed ID: 28906207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.
    Mudireddy M; Gangat N; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Blood Cancer J; 2018 Jun; 8(6):57. PubMed ID: 29891917
    [No Abstract]   [Full Text] [Related]  

  • 52. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
    Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
    Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
    Shrestha R; Giri S; Armitage JO; Bhatt VR
    Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostication in MF: from CBC to cytogenetics to molecular markers.
    Zhou A; Oh ST
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(18):8629-31. PubMed ID: 26745128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.